Lydia Newton
@lsnewton.bsky.social
Postdoctoral Research Fellow in the Towers Lab at UCL @towerslab.bsky.social
Pinned
Lydia Newton
@lsnewton.bsky.social
· Feb 14
Happy to announce that our 2nd paper of 2025 is out! 🎊
This collaboration between our brilliant postdoc @lsnewton.bsky.social and @claragathmann.bsky.social, from Dave Selwood’s chemistry lab, designs and employs PROTACs to degrade CypA and inhibit HIV and HCV.
www.nature.com/articles/s41...
This collaboration between our brilliant postdoc @lsnewton.bsky.social and @claragathmann.bsky.social, from Dave Selwood’s chemistry lab, designs and employs PROTACs to degrade CypA and inhibit HIV and HCV.
www.nature.com/articles/s41...
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV - Nature Communications
Targeted protein degradation has so far been rarely applied as an antiviral strategy. Here, the authors report that macrocycle-based PROTACs targeting host protein cyclophilin A, exploited during vira...
www.nature.com
My PhD work is now published!
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
Reposted by Lydia Newton
New preprint from our lab, led by our postdocs Dara Annett and Kate Morling in collaboration with Selwood Lab!
We developed a modified cyclosporine, BG147, which enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3. Check it out!
We developed a modified cyclosporine, BG147, which enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3. Check it out!
A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3
Intrinsic innate immune barriers have evolved to suppress viral infection and can reduce effective gene delivery in gene therapy. We have developed BG147, a novel cyclosporine A analogue, optimised vi...
www.biorxiv.org
September 29, 2025 at 3:38 PM
New preprint from our lab, led by our postdocs Dara Annett and Kate Morling in collaboration with Selwood Lab!
We developed a modified cyclosporine, BG147, which enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3. Check it out!
We developed a modified cyclosporine, BG147, which enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3. Check it out!
Reposted by Lydia Newton
We are delighted to be joining the Blizard Institute in Autumn. The Blizard Institute is an amazing place for discovery science and we're looking forward to more transformative research and collaborations.
www.qmul.ac.uk/blizard/abou...
www.qmul.ac.uk/blizard/abou...
Blizard Institute welcomes world-leading team of virologists
www.qmul.ac.uk
July 10, 2025 at 1:05 PM
We are delighted to be joining the Blizard Institute in Autumn. The Blizard Institute is an amazing place for discovery science and we're looking forward to more transformative research and collaborations.
www.qmul.ac.uk/blizard/abou...
www.qmul.ac.uk/blizard/abou...
Reposted by Lydia Newton
Towers Lab attending @londoninfectionecr.bsky.social (LINE) annual symposium. Great talk lineups at the Francis Crick Institute, London. #LINE #ScienceIsCool.
June 9, 2025 at 12:42 PM
Towers Lab attending @londoninfectionecr.bsky.social (LINE) annual symposium. Great talk lineups at the Francis Crick Institute, London. #LINE #ScienceIsCool.
Reposted by Lydia Newton
Virtual Virology is back - our first ever phage session. Do join us...
May 8, 2025 at 6:09 PM
Virtual Virology is back - our first ever phage session. Do join us...
Reposted by Lydia Newton
Great seeing our recent antiviral PROTAC paper chosen by Nature Comms Editors as one of the 50 best papers in Microbiology and Infectious Diseases!
www.nature.com/collections/...
www.nature.com/collections/...
Microbiology and infectious diseases
This page highlights recent articles on all aspects of bacteriology, mycology, parasitology and virology, covering the biology of pathogens, host-pathogen ...
www.nature.com
March 5, 2025 at 4:16 PM
Great seeing our recent antiviral PROTAC paper chosen by Nature Comms Editors as one of the 50 best papers in Microbiology and Infectious Diseases!
www.nature.com/collections/...
www.nature.com/collections/...
Reposted by Lydia Newton
Antiviral drug development:
Small molecules inducing degradation of host protein cyclophilin A show #antiviral activity against HIV-1 & HCV
@towerslab.bsky.social @lsnewton.bsky.social @claragathmann.bsky.social
@jollylab.bsky.social @alessiociulli.bsky.social
www.nature.com/articles/s41...
Small molecules inducing degradation of host protein cyclophilin A show #antiviral activity against HIV-1 & HCV
@towerslab.bsky.social @lsnewton.bsky.social @claragathmann.bsky.social
@jollylab.bsky.social @alessiociulli.bsky.social
www.nature.com/articles/s41...
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV - Nature Communications
Targeted protein degradation has so far been rarely applied as an antiviral strategy. Here, the authors report that macrocycle-based PROTACs targeting host protein cyclophilin A, exploited during vira...
www.nature.com
February 28, 2025 at 3:01 PM
Antiviral drug development:
Small molecules inducing degradation of host protein cyclophilin A show #antiviral activity against HIV-1 & HCV
@towerslab.bsky.social @lsnewton.bsky.social @claragathmann.bsky.social
@jollylab.bsky.social @alessiociulli.bsky.social
www.nature.com/articles/s41...
Small molecules inducing degradation of host protein cyclophilin A show #antiviral activity against HIV-1 & HCV
@towerslab.bsky.social @lsnewton.bsky.social @claragathmann.bsky.social
@jollylab.bsky.social @alessiociulli.bsky.social
www.nature.com/articles/s41...
My PhD work is now published!
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
Happy to announce that our 2nd paper of 2025 is out! 🎊
This collaboration between our brilliant postdoc @lsnewton.bsky.social and @claragathmann.bsky.social, from Dave Selwood’s chemistry lab, designs and employs PROTACs to degrade CypA and inhibit HIV and HCV.
www.nature.com/articles/s41...
This collaboration between our brilliant postdoc @lsnewton.bsky.social and @claragathmann.bsky.social, from Dave Selwood’s chemistry lab, designs and employs PROTACs to degrade CypA and inhibit HIV and HCV.
www.nature.com/articles/s41...
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV - Nature Communications
Targeted protein degradation has so far been rarely applied as an antiviral strategy. Here, the authors report that macrocycle-based PROTACs targeting host protein cyclophilin A, exploited during vira...
www.nature.com
February 14, 2025 at 1:25 PM
My PhD work is now published!
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
We designed PROTACs that degrade the viral cofactor CypA and demonstrated their antiviral activity against HIV & HCV. We anticipate broad efficacy against unrelated viruses and reduced evolution of viral resistance. They also make excellent tools to probe Cyp biology.
Reposted by Lydia Newton
Today @gogs-k.bsky.social, @tlhr.bsky.social, and I are launching @bindresearch.org, a UK-based not-for-profit research startup to deliver publicly–available tools and datasets to make intrinsically disordered proteins druggable. 🍝 💊🧲 💻 🦠
February 11, 2025 at 9:26 AM
Today @gogs-k.bsky.social, @tlhr.bsky.social, and I are launching @bindresearch.org, a UK-based not-for-profit research startup to deliver publicly–available tools and datasets to make intrinsically disordered proteins druggable. 🍝 💊🧲 💻 🦠